We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
New Zealand rickettsia‐like organism and Tenacibaculum maritimum vaccine efficacy study.
- Authors
Jaramillo, D.; Busby, B. P.; Bestbier, M.; Bennett, P.; Waddington, Z.
- Abstract
A cohort of Chinook salmon juveniles was vaccinated, with an autogenous bivalent vaccine against New Zealand RLOs (NZ‐RLO1) and Tenacibaculum maritimum. A proportion of the cohort was not vaccinated to act as controls. At smoltification, the fish were challenged with NZ‐RLO1, NZ‐RLO2, or T. maritimum. We found that challenge with T. maritimum by immersion in (7.5 × 105 cfu/mL of water) did not yield any pathology. Challenge with RLOs produced clinical signs that were more or less severe depending on the challenge route, dose or vaccination status. Survival was significantly higher for vaccinated fish within the groups challenged with NZ‐RLO1 by intraperitoneal injection with a relative percent survival (RPS) of 48.84%. Survival was not significantly different between vaccinated and non‐vaccinated fish for groups challenged with NZ‐RLO2 by intraperitoneal injection or by NZ‐RLO1 by immersion. Yet, anecdotally the clinical disease presentation (manifesting as haemorrhagic, ulcerative skin lesions) was more severe for the non‐vaccinated fish. This study demonstrates that autogenous vaccine against NZ‐RLO is protective against severe disease and death by NZ‐RLO1 challenge which warrants implementation and further evaluation under field conditions. Yet, this study also highlights the importance of the route of administration and dose when evaluating pathogenicity and vaccine efficacy.
- Subjects
NEW Zealand; VACCINE effectiveness; VACCINATION status; CHINOOK salmon; INTRAPERITONEAL injections; SMOLTING; RICKETTSIA
- Publication
Journal of Fish Diseases, 2024, Vol 47, Issue 2, p1
- ISSN
0140-7775
- Publication type
Article
- DOI
10.1111/jfd.13883